Pompe Disease Stocks List

Related Stock Lists: Cancer Enzyme Replacement Therapy Gaucher Disease Inborn Errors Of Metabolism Medicine Rare Diseases Achondroplasia Autoimmune Disease Biomarin Pharmaceutical Biopharmaceutical Biopharmaceuticals Bristol Myers Squibb Cac 40 Chronic Kidney Disease Colorectal Cancer Consumer Health Care Products Deep Vein Thrombosis Dialysis Drug Discovery Enzyme Replacement Therapies

Recent Signals

Date Stock Signal Type
2020-05-27 BMRN New 52 Week Closing High Bullish
2020-05-27 BMRN Upper Bollinger Band Walk Strength
2020-05-27 BMRN Jack-in-the-Box Bullish Bullish Swing Setup
2020-05-27 FOLD 20 DMA Support Bullish
2020-05-27 FOLD Hammer Candlestick Bullish
2020-05-27 FOLD Slingshot Bullish Bullish Swing Setup
2020-05-27 FOLD Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2020-05-27 FOLD 180 Bullish Setup Bullish Swing Setup
2020-05-27 SNY Cup with Handle Other

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

More about Pompe Disease